	Subgroup	HR(95%CI)	CDS	S vs Non-CDS			Р
Age	<64	0.50(0.38-0.66)	HH4				<0.001
	65-74	0.61(0.43-0.85)	H=-1				0.018
	≥75	0.41(0.25-0.68)					0.004
Sex	Female	0.47(0.35-0.63)	H=4				<0.001
	Male	0.59(0.45-0.76)	н				<0.001
Race	Non-white	0.51(0.30-0.86)	н				0.034
	White	0.53(0.43-0.65)	HH.				<0.001
Marital status	Divorced/widowed	0.35(0.21-0.58)	н				<0.001
	Married	0.55(0.43-0.70)	н				<0.001
	Unmarried	0.62(0.39-0.97)	H=				0.081
Primary site	Overlapping/NOS	0.64(0.33-1.28)		ı			0.295
	Bronchus	0.80(0.21-3.09)					0.787
	Lobe	0.51 (0.41-0.62)	1001				<0.001
Grade	I-II	0.31(0.21-0.45)	HIH.				<0.001
	III-IV	0.71(0.53-0.94)	H=H				0.05
	Unknown	0.54(0.35-0.80)	HI-H				0.011
T stage	T1	0.54(0.34-0.83)	+=-4				0.021
	T2	0.52(0.36-0.73)	HH-H				0.002
	Т3	0.37(0.24-0.56)	нн				<0.001
	T4	0.89(0.57-1.39)		4			0.67
	TX	0.35(0.15-0.81)					0.038
N stage	N0-1	0.39(0.29-0.52)	<b>III</b>				<0.001
	N2	0.67(0.49-0.92)	H <del></del> -1				0.038
	N3	2.42(0.99-5.88)	-	-		—	0.101
	NX	0.16(0.04-0.59)					0.022
Radiotherapy	No/Unknown	0.46(0.35-0.59)	HIIII				<0.001
	Yes	0.64(0.48-0.87)	+=-1				0.018
Chemotherapy	No/Unknown	0.34(0.23-0.51)	HIIH				<0.001
	Yes	0.61(0.47-0.76)	HIH				<0.001
			0 1	2 3	4	5 6	
	CDS better Non-CDS better						

Figure S1 Subgroup analysis for cancer-specific survival in different subgroups. HR, hazard ratio; CI, confidence interval; CDS, cancer-directed surgery.